Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Wilms Tumor 9Prostatic Neoplasms 9Glioma 9Osteosarcoma 8Neuroblastoma 8Multiple Myeloma 8Leukemia, Myeloid, Acute 8Sarcoma 7Rhabdoid Tumor 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Carcinoma, Hepatocellular 5Sarcoma, Ewing 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3

Interventions

Cyclophosphamide 32Vincristine 22blinatumomab 20Methotrexate 20Specimen Handling 19Prednisone 19Cytarabine 17merphos 16prednylidene 15deltacortene 15Biopsy 15Mercaptopurine 14Doxorubicin 14Dexamethasone 14N,N-dicyclohexyl-isoborneol-10-sulfonamide 13pegaspargase 12azathiopurine 12Rituximab 12Etoposide 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11Spinal Puncture 11Calcium Dobesilate 11Asparaginase 11Leucovorin 10fludarabine 9Magnetic Resonance Spectroscopy 9Inotuzumab Ozogamicin 9Daunorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Burkitt Lymphoma × X-Rays × 90 days × Clear all
NCT02981628 2026-06-05

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02143414 2026-05-28

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
53 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡